?Product Overview?
Ozagrel Sodium (CAS: 189224-26-8) is a ?sodium salt form of Ozagrel?, a selective ?thromboxane A2 synthase inhibitor? with the molecular formula ?C??H??N?NaO?? (MW: 250.23). It effectively reduces platelet aggregation and vasoconstriction by blocking thromboxane A2 synthesis, making it a critical agent for treating ?cerebral thrombosis? and ?acute ischemic stroke?. Available as a white crystalline powder, it is widely utilized in clinical and pharmaceutical research for thrombosis-related therapies.

? ?Key Advantages?
? ?High Purity?: ≥99% (HPLC/GC verified), ensuring pharmaceutical-grade compliance.
? ?Targeted Action?: IC?? of ?4 nM? against thromboxane A2 synthase, offering precise therapeutic effects.
? ?Stable Storage?: Maintains integrity at ?2–8°C? (protected from light) or ?-20°C? for long-term preservation.

?? ?Application Fields?

• ?Clinical Treatment?: Primary use in managing ?cerebral thrombosis? and ischemic cerebrovascular diseases.

• ?Mechanistic Research?: Study of platelet aggregation pathways and thromboxane-related pathologies.

• ?Drug Development?: Intermediate for synthesizing advanced antithrombotic medications.

?? ?Quality Certifications?

• Manufactured in ?GMP-certified facilities?, compliant with ?USP/EP/BP standards?.

• Rigorously tested via ?HPLC, NMR, and mass spectrometry? for identity and purity.

• Adheres to ?MSDS guidelines? for safe handling, storage, and transportation.

?? ?Market Insights?
The global antithrombotic drug market is projected to reach ?$45.7B by 2030? (CAGR 6.8%), driven by rising cardiovascular disease prevalence and demand for targeted therapies. Ozagrel Sodium’s efficacy in acute thrombotic events positions it as a vital therapeutic option.